Skip to main content
OpenTrials
Completed

NCT Number: NCT07284043

A Mass Balance Study of [14C] MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism

MT1013 is a first-in-class dual-target agonist.This study is being conducted to determine the mass balance and routes of excretion of total radioactivity after the dose of [14C] MT1013.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

The First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital)

Jinan, Shandong, 250014, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1. Male or postmenopausal female participants, aged 18 years or older, with a confirmed diagnosis of SHPT.
  • 2. The BMI is between 18 kg/m2 and 35 kg/m2;
  • 3. The subjects must undergo regular maintenance hemodialysis three times a week for at least three months;
  • 4. Within 14 days prior to randomization, subjects must have serum calcium levels≥ 8.4 mg/dL;
  • 5.Subject capable of understanding written information ,willing to participate in, and provide a written informed consent;

Exclusion criteria

  • 1. The subjects underwent parathyroidectomy within 6 months prior to screening, or plan to undergo parathyroidectomy or ablation or radiation during the study;
  • 2. Gastrointestinal bleeding or peptic ulcer medical history within 6 months prior to screening;
  • 3. The subjects had myocardial infarction or had undergone coronary angioplasty or coronary artery bypass grafting within 6 months before screening.
  • 4.Subjects with severe uncontrolled hypertension, defined as systolic blood pressure>180 mmHg and/or diastolic blood pressure>110 mmHg;
  • 5. History of epileptic seizures or ongoing epilepsy related treatment within 1 year prior to screening;
  • 6. History of malignant tumors within the five years prior to screening;
  • 7. The subjects received oral cinacalcet or ivocalcet within 7 days before signing the informed consent form, or received Etelcalcetide injection treatment within 4 months.
  • 8. Engaged in work that requires long-term exposure to radioactive conditions; Or those who have had significant radioactive exposure or participated in radioactive drug labeling tests within one year prior to screening;
  • 9. Participants who may not be able to complete this study for other reasons or who the researchers consider should not be included.

Treatment and study plan

[14C] MT1013/MT1013 Injection

Drug

[14C] MT1013/MT1013 Injection

Primary outcomes

  1. Cumulative excretion of radioactivity

    Time frame: Day 1 to Day 91.

  2. Percentage of parent drug and its metabolites in plasma as a percentage of total radioactive exposure (%AUC)

    Time frame: Day 1 to Day 91.

Secondary outcomes

  1. Adverse Events (AEs)

    Time frame: About 13 weeks.

  2. Serious adverse Events (SAEs)

    Time frame: About 13 weeks.

Sponsors and collaborators

Lead sponsor

Shaanxi Micot Pharmaceutical Technology Co., Ltd.

Industry

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Dec 16, 2025
Registry last updated
Jul 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.